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Edited by Laszlo NagyAbstract Autotaxin is a member of the phosphodiesterase fam-
ily of enzymes, (NPP2). It is an important secreted protein found
in conditioned medium from adipocytes. It also has a putative
role in the metastatic process. Based on these observation, fur-
ther validation of this potential target was necessary, apart from
the classical biochemical ones. The construction of a knock out
mouse strain for ATX was started. In this paper, we report the
generation of a mouse line displaying an inactivated ATX gene
product. The KO line was designed in order to generate a func-
tional inactivation of the protein. In this respect, the threonine
residue T210 was replaced by an alanine (T210A) leading to a
catalytically inactive enzyme. If the experimental work was
straight forward, we disappointedly discovered at the ﬁnal stage
that the breeding of heterozygous animals, ATX /+, led to the
generation of a Mendelian repartition of wild-type and heterozy-
gous, but no homozygous were found, strongly suggesting that
the ATX deletion is lethal at an early stage of the development.
This was conﬁrmed by statistical analysis. Although other re-
ported the same lethality for attempted ATX/ mice genera-
tion [van Meeteren, L.A., Ruurs, P., Stortelers, C., Bouwman,
P., van Rooijen, M.A., Prade`re, J.P., Pettit, T.R., Wakelam,
M.J.O., Saulnier-Blache, J.S., Mummery, C.L., Moolenar,
W.H. and Jonkers, J. (2006) Autotaxin, a secreted lysophospho-
lipase D, is essential for blood vessel formation during develop-
ment, Mol. Cell. Biol. 26, 5015–5022; Tanaka, M., Okudaira,
S., Kishi, Y., Ohkawa, R., Isei, S., Ota, M., Noji, S., Yatomi,
Y., Aoki, J., and Arai, H. (2006) Autotaxin stabilizes blood ves-
sels and is required for embryonic vasculature by producing lyso-
phosphatidic acid, J. Biol. Chem. 281, 25822–25830], they used
more drastic multiple exon deletions in the ATX gene, while we
chose a single point mutation. To our knowledge, the present
work is the ﬁrst showing such a lethality in any gene after a point
mutation in an enzyme catalytic site.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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ATX is a lyso-phospholipase D enzyme originally described
as a motility factor [1]. Since the discover, by others [2,3] and*Corresponding author. Fax: +33 1 55 72 28 10.
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doi:10.1016/j.febslet.2007.06.064by us [4] that this enzyme catalyzes a lyso-phospholipase D
(LPD) activity leading to the transformation of lyso-phosphat-
ildylcholine into LPA, the role of this protein seemed to be
central in some key metabolic deregulations (see Moolenaar
for reviews [5,6]), particularly since it is over-expressed in the
conditioned medium of adipocytes in culture [7]. ATX could
be the main enzymatic source for the production of LPA,
the role of which in metastasis has just been demonstrated
[8]. Furthermore, it is known for quite some times that the
LPA concentration is proportional to the metastasis progres-
sion, and therefore to cancer prognosis (see Jansen et al. [9]
for complete references). Finally, even more direct evidences
associated the expression of ATX with breast cancer invasive-
ness [10,11].
While making other attempts to provide more validation in
term of involvement of this enzyme in diabesity [12], we at-
tempted to knock-out the gene in mouse. This would have pro-
vide us with further validation towards the therapeutical use of
this new target, beside biochemical [4] and pharmacological
studies [13].
ATX has been described in the past as a motility factor [14].
Indeed, autotaxin was suspected to act through a putative
receptor, before the discovery of its lyso-PLD catalytic activ-
ity. Hence, the presence of a RGD motif in the sequence
pointed to the possibility that the protein itself might also
act as a ligand or a partner to another protein. We therefore
suspected that the deletion of a part of the protein might have
deleterious eﬀect on the mouse development. Since previous
data evidenced that the point mutation inside the catalytic site
(threonine 210 to alanine) leads to a catalytically inactive en-
zyme [15,16], we decided to reproduce this point mutation
in vivo in order to circumvent any deleterious eﬀect that the
ATX gene classical disruption approach may have. Despite
many diﬃculties in generating ATX targeted ES cells, we ﬁnal-
ly only succeeded in generating heterozygous mice with a single
loss of ATX gene, whereas no homozygous mice were pro-
duced. This strongly suggests that the ATX T > A210 mutation
is lethal at the homozygous stage.2. Materials and methods
2.1. Construction of the targeting vector
Targeting vector construction and knock-in strategy has been de-
signed and performed by genOway (Lyon, France). Genomic clones
containing the murine Atx locus were isolated from a 129S6/SvEvTac
RPCI-22 BAC genomic library by using probe corresponding to theblished by Elsevier B.V. All rights reserved.
Fig. 1. Targeted mutation of the Atx gene produces a null mutation. The Atx locus (containing the exons 4–8) and the targeting construct
(containing the neomycin Tk(PGK-NeoTK) cassette with ﬂanking segments homologous to the locus) are shown in schematic format. The
transcriptional orientation of neomycin-TK cassette and the Atx locus are delineated by arrows. The probe used in all the Southern blot analysis is a
1.0-kb fragment located in a region overlapping exon 7. B: BgIII site; K: KnpI site; P: PacI site, S: SacI site, W: SwaI site. The arrow head
corresponds to the LoxP site.
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taining Atx locus have been isolated. The genomic organization of the
targeted locus was determined by subcloning BglII–SacI genomic
fragment into the pZErO-2 vector (Invitrogen, Carlsbad, CA). The
6.6-kb BglII–SacI genomic insert was sequenced and Atx sequence
was generated. The genomic clone (containing introns V–VIII) was
used to construct the targeting vector. Brieﬂy, a 1.3-kb SwaI–PacI
fragment comprising Atx exons 6 and 7 and a 4.6-kb PacI–SacI frag-
ment located downstream of the Atx seventieth exon, were used to
ﬂank a NEO-tk cassette (LoxP site-PGK promoter-Neo-tk fusion
cDNA-LoxP site) (as shown in Fig. 1); a negative (DTA) selection cas-
sette was introduced at the 5 0 of the short arm of homology. A
T > A210 point mutation was introduced into the Atx exon 7 using
QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla,
CA).
Furthermore, we cloned from 129S6/Sv mouse brain the ATX cod-
ing region into pcDNA3 vector and introduced by directed mutagene-
sis the T > A210 mutation. We further used the two vectors, wild-type
and mutated one, for expression in COS cells. As an internal control,
we used a pcDNA3 vector containing the ATX sequence largely de-
leted from amino acids 202 to 363, which corresponds to the deletion
of the whole catalytic site.
2.2. Screening of Atx targeted ES cell clones
AvrII-linearized targeting vector was transfected into 129SvPas ES
cells (genOway, Lyon, France) according to genOway’s modiﬁed elec-
troporation procedures (i.e. 108 ES cells in presence of 100 lg of line-
arized plasmid, 260 V, 500 lF). Positive selection was started 48 h after
electroporation, by addition of 200 lg/ml of G418 (150 lg/ml of active
component, Life Technologies, Inc.). Three hundred and thirty-one
resistant clones were isolated and ampliﬁed in 96-well plates. The
duplicates of 96-well plates were made. The set of plates containing
ES cell clones ampliﬁed on gelatin were screened by PCR and further
conﬁrmed by Southern blot. 5 0 PCR screening conditions were:
GW735 primer hybridizes the Atx intron 5 (5 0-GGCGACAGCC-
ACATTGAGTGACAC-30), and GW736 primer is speciﬁc for theNeo-Tk selection cassette (5 0-CGGTGGATGTGGAATGTGTGCG-
3 0). PCR conditions are 94 C/5 min, 35 cycles of (92 C/30 s, 62 C/
30 s, 68 C/4 min 30 s) and then 68 C/10 min, which results in a
2046-bp band for the mutated allele; PCR reaction is performed using
Long Expand High Fidelity polymerase (Roche) and reaction buﬀer
3. The 3 0 PCR screening conditions were: GW686 primer is speciﬁc for
the neomycin-tk selection cassette (5 0-GGTGGAGAGGCTATTC-
GGCTATGAC-3 0), and GW773 primer is speciﬁc for the Atx intron
7 (5 0-CTCCTGCCTCCACATTCCTTCCCTG-3 0). PCR conditions
are 94 C/2 min, 35 cycles of (94 C/30 s, 65 C/30 s, 68 C/6 min) and
then 68 C/7 min, which results in a 6096-bp band for the mutated al-
lele; PCR reaction is performed using Long Expand High Fidelity
polymerase (Roche) and reaction buﬀer 3. Brieﬂy, for Southern blot
analysis, genomic DNA was digested with SpeI–KpnI and then hybrid-
ized with a 1.0-kb internal probe; Atx+/ clones give rise to an 11.3-kb
wild-type signal and 8.1-kb + 5.3-kb targeted signals. The presence of
the T > A210 point mutation was conﬁrmed by sequencing the 5 0 PCR
amplicon. Four clones (#4E6, 4G1, 3B4 and 3D1) were identiﬁed, by
both PCR and Southern blot as targeted at the Atx locus (Fig. 2).
2.3. Generation of Chimera mice and breeding scheme
One ﬂoxed mutated Atx ES cell clone (namely #3B4) was microin-
jected into C57BL/6 blastocysts, and gave rise to male chimeras with
a signiﬁcant ES cell contribution (as determined by an Agouti coat
color). After mating with C57Bl/6 females, germ line transmission
was conﬁrmed by the genotyping of tail DNA oﬀsprings using PCR
and Southern blot analysis. Floxed heterozygous animals were
screened as described in previous chapter (Fig. 3). F1 male heterozy-
gous animals were bred with C57/Bl6 CMV-Cre expressing female
mice in order to remove the LoxP-ﬂanked Neo cassette. Oﬀsprings
were genotyped by PCR and Southern blot in order to ensure the
Neo cassette removal. PCR screening conditions are: the GW741 pri-
mer is speciﬁc for the 3 0 region of intron 6 (5 0-CCTACAT-
GAGGCCTGTGTACCCTACAAAAG-3 0), and the GW742 primer
is speciﬁc for intron 7 (5 0-GTCTGAGTTTCATCCCAGAACCCG-
TATG-3 0). PCR conditions are 94 C/2 min, 35 cycles of (94 C/30 s,
Fig. 2. PCR screening on 5 0 and 3 0 end of homologous recombination event. The PCR screening on 5 0 and 3 0 end of homologous recombination
event is shown for ES cell clones #4E5, #4E6, #4G1, #3B4, #3B10 and #3D1. The 2046-bp and 6096-bp bands signify appropriated targeted
disruption of mAtx locus on 5 0 and 3 0 end targeting event, respectively. Southern blot analysis of positive and wild-type ES cell clones. Digestion of
genomic DNA with KpnI–SpeI resulted in the following diagnostic fragment: wild-type allele of 11.3-kb band, appropriate targeting of theAtx locus
of 8.1- and 5.3-kb band.
Fig. 3. PCR screening analysis of the oﬀspring of Atx-mutated mice. The PCR screening analysis of the oﬀspring of Atx-mutated mice displaying the
ﬂoxed Neo cassette mice with CMV-Cre expressing mice. They were performed on biopsy tails of the pups. The 600-bp band corresponds to the
mutated Atx Neo excised allele, the 470-bp band corresponds to the Atx wild-type allele, while the 3700-bp band corresponds to the mutated Atx
ﬂoxed allele.
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bp wild-type signal, a 600-bp Neo excised signal and 3700-bp ﬂoxed
signal; PCR reaction is performed using Long Expand High Fidelity
polymerase (Roche) and reaction buﬀer 2. Brieﬂy, for Southern blot
analysis, genomic DNA was digested with KpnI–SpeI and then hybrid-
ized with a 1.0-kb internal probe; Atx+/ clones produced an 11.3-kb
wild-type signal and 6.1-kb + 5.3-kb targeted Neo-excised signals. F1
male and female heterozygous animals were interbred to obtain Atx-
mutant mice. Animals were screened by PCR and Southern blot anal-
ysis as described above (Fig. 4).2.4. Mutated autotoxin expression and measure of autotoxin catalytic
activity
Standard transfection procedures were used in a further set of exper-
iments. Using Lipofectamin, we transfected several batches of cells.
The cells were cultured for a further 24 h. Transfected COS-7 cells were
washed twice with phosphate-buﬀered saline to remove serum and
incubated (5 ml for a 10-cm diameter plate; 1 ml for a 3-cm diameter
plate) in serum-free DMEM at 37 C in a humidiﬁed atmosphere con-
taining 5% CO2. The conditioned media were separated from the cellscentrifuged to eliminate cell debris, and stored at 20 C until further
use [4]. The fractions were then concentrated and submitted either to
SDS–PAGE electrophoresis and Western blot using an anti ATX anti-
body. Both ATX catalytic activities were measured on this material
either the phosphodiesterase or the lysophospholipase D ones, with a
colorimetric assay or a thin layer chromatographic assay, respectively,
[4]. In brief, the phosphodiesterase activity of ATX was measured by
using pNPPP as substrate in test using a modiﬁcation of the method
of Razzell and Khorana (15). Samples (100 ll) were incubated in 96-
well plate with p-nitrophenyl phenylphosphonate at a 5 mM ﬁnal con-
centration in a 50 mM Tris–HCl, pH 9.0 buﬀer. After 30 min at 37 C,
reactions were stopped by addition of 100 ll of 0.1 M NaOH. The pro-
duction of p-nitrophenol was kinetically quantiﬁed by reading the
absorbance at 410 nm using a Pherastar plate reader (BMG, Germany)
with the appropriate controls. Lysophospholipase D activity was mea-
sured by conversion of radiolabeled LPC into radiolabeled LPA. A
solution of [14C] palmitoyl-lysophosphatidylcholine (Perkin-Elmer Life
Sciences; 55.8 mCi/mmol) at 0.0025 lCi/lL in DMEM supplemented
with 1% free fatty acid BSA was ﬁrst prepared, and 20 lL of this solu-
tion was incubated with 500 ll of thawed CM plus 1 ll of sodium
orthovanadate (0.5 mM) for 90 min at 37 C. At the end of the incuba-
Fig. 4. Southern blot analysis of the oﬀspring of Atx ﬂoxed mice with CMV-Cre expressing mice. Digestion of tail DNA by KpnI–SpeI resulted in
the following diagnostic fragment: wild-type band of 11.3-kb, Neo excised allele bands of 6.1- and 5.3-kb.
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evaporated, spotted on a silica gel 60 TLC glass plate (Merck), and
separated using CHCl3/MeOH/NH4OH (60:35:8) as the migration sol-
vent. The plates were autoradio-graphed overnight at 80 C using a
Biomax-MS ﬁlm (Kodak) to localize radiolabeled LPA spots, which
were scraped and counted with 3 ml of scintillation mixture.3. Results and discussion
L1ES cell clone #3D1-40 bearing the Atx-mutated allele and
transfected with CRE expressing plasmid in order to remove
the LoxP ﬂanked Neo selection cassette, was injected into
121 blastocysts in order to generate Neo-excised Atx knock-
in chimeras. It gave rise to the generation of two male chimeras
with a 40% chimerism rate. As no agouti mouse was generated
from a total of 8 F1 litters, we decided to inject the parental ES
cell clones B4, 3D1 and 4G1 harbouring the mutated allele and
containing the Neo cassette. This approach was conducted in
order to overcome any problem that could have been occurred
because of the second round of electroporation of the ES.
Three parental ES cell clones (#3B4, 3D1 and 4G1) bearing
the mutated Atx allele were injected into 75 blastocysts. Only
ES cell clone #3B4 gave rise to seven pups. Three male chime-
ras, were identiﬁed with chimerism rates of 90%, 80% and 60%.
These chimeras were then mated with CMV-Cre expressing
C57Bl/6 females in order achieve to the Neo cassette deletion
in vivo. Breeding of the ES cell clone #3B4 chimeras resulted
in the generation of 65 mice from which 40 were agouti (17
males and 23 females). PCR screening revealed they were all
wild-type. At that stage, since the size of the litters was not
unusual, it seemed that the modiﬁcation of the ATX locusTable 1
Summary of mutated autotaxin homozygous breeding
Mating pairs Attempt # Pups Stillborns
Triad 1 1 6 0
2 8 1
3 9 1
4 8 0
Triad 2 1 5 0
2 7 0
3 9 0
Note: each triads were composed of 1 male and 2 females, all heterozygous fo
m: male; f: female.did not cause any mortality. We hypothesized that the cause
of the failure was the slow growing of the ATX mutated ES
cells or a potential mixture between the targeted ES cells and
wild-type ES cells. More blastocysts were injected with a new
lot of ES cells, re-implanted in three gestating females. One
out of these three females gave birth again to seven pups.
Three male chimera were identiﬁed with better chimerism rate
than previously, i.e. 85%, 90% and 95%. The three males were
mated with three wild-type C57/Bl6 females each. This breed-
ing resulted in the generation of 12 agoutis mice (10 males, 2
females) derived from the 90% chimera. These 12 agoutis F1
mice were screened by Southern blot for heterozygous charac-
terization. Three males and one female were identiﬁed there-
fore suggesting the germline transmission of the mutation
and suggesting that the failure in obtaining heterozygous mice
from the previous chimeras should be linked to an impaired
ability of the ATX-targeted ES cells to colonize the blastocyst
and to give to germline transmission. Such germline transmis-
sion was unexpected when compared to other KO projects
developed concomitantly using the same batch of ES cells.
Two of the males were used to produce the F2 generation as
above. These males were mated with 2 CMV-Cre-expressing
129v mice each. This resulted in the generation of 47 mice
(26 males and 21 females) which were screened for the Cre-
mediated excision by PCR and Southern blot. As expected,
PCR revealed a band shift from 3.7 kb to 0.6 kb suggesting
the Cre-mediated excision of the targeted allele as illustrated
on Fig. 4 for six animals. The animals analyzed in lanes 1
and 5 harboured the Cre-mediated excision. At the end of this
process, out of 51 pups, 15 heterozygous animals were identi-
ﬁed (11 males and 5 females). Two of these heterozygous malesWild types Heterozygous Homozygous
5 (1m + 4f) 1 (1m) Nil
2 (1m + 1f) 5 (2m + 3f) Nil
3 (1m + 2f) 5 (2m + 3f) Nil
5 (2m + 3f) 3 (2m + 1f) Nil
3 (1m + 2f) 2 (1m + 1f) Nil
3 (2m + 1f) 4 (3m + 1f) Nil
1 (1f) 8 (4m + 4f) Nil
r autotaxin mutation. The attempts were separated by at least 3 weeks.
Table 2
F3 genotypes representation v2 analysis
Hypothesis Theoretical number of animals Real number of animals Calculated
v2 values
Table
v2 values
+/+ +/ / +/+ +/ /
Viable homozygous 13 25 12 22 28 0 18.59 5.99 (5%)
9.21 (1%)
Embryonic lethal
homozygous
17 33 N/A 22 28 0 2.23 3.84 (5%)
6.63 (1%)
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resulted in the generation of seven litters of 5–9 pups each.
All of them were tail-genotyped. No homozygous, ATX/,
animals were born (see Table 1 for details). Considering these
results as well as results obtained before, we hypothesized that
the ATX deletion was lethal. In order to evaluate statistically
this possibility, a v2 test was summarized in Table 2.
Such lethality features in deleted mice strain have been scar-
cely reported in the literature: the main ones were retinalde-
hyde dehydrogenase-3 [17], the ribosomal protein S19 [18],
MAPK [19], Acetyl-CoA carboxylase 1 [20], hexokinase I
[21] and a review on attempts around checkpoint-associated
proteins, i.e. ATR, chk1, Mad2, NBS, BRCA1 and 2 or Rad5
[22]. Furthermore, Argraves and Drake reviewed a large panel
of lethal situations due to the knock-out of vascular-related
genes in mice [23]. They signed the importance of the pathway
in which the target gene has been modiﬁed or deleted. Con-
cerning ATX, such a result was deceptive but not really sur-
prising, since the catalytic activity of ATX might provide the
major source for lyso-phosphatidic acid from lyso-phosphati-
dylcholine. The cellular responses to LPA are remarkably di-
verse from cell proliferation and survival to induction of
neurite retraction and inhibition of gap functional communica-Fig. 5. Expression and catalytic activity of the recombinant autotaxin wild-
D202–363) were constructed in pcDNA3 vectors. COS cells were transfected a
of the mutated proteins and for their activity, either lysophospholipase D or
from wild-type (wt), ATX T210A (three lanes) and ATX D202–363. (B) L
biological sources; right panel: lysophospholipase D activities (open symbo
symbols: ATX T210A -transfected cell-derived conditioned media and closetion (see Moolenaar [5] and Contos et al. [24] for reviews). De-
spite this, the targeted, concomitant deletion of one or two
LPA receptors has been reported [25,26]. Surprisingly, the
lpa1/ strain presented a series of strong altered traits in their
phenotypes, including a 50% neonatal lethality [25], while the
double KO lpa1//lpa2/ strain did not present additional
phenotypic traits. The lpa3/ obtention shaded some light
on the possible implication of LPA in embryo implantation
[27]. Indeed, such a feature points at a possible key role
of LPA into nidiﬁcation and/or implantation through one of
the LPA receptors. On the other hand, the implication of
ATX in the blood vessel development was also reported [28]
and also might explain the early lack of embryonic implanta-
tion and/or development. Conversely, the early death of em-
bryos, or even the lack of development thereof is also an a
posteriori proof that ATX plays a key role in the production
of LPA. Autotaxin might well be the unique source of LPA
at least at early stages of the embryonic life. Previous KO at-
tempts of ATX in mice have been very recently reported
[29,30]. While there are evidences that ATX is circulating in
blood [31] and that LPA production is massively – if not un-
iquely – by ATX catalytic activity, the role of the ATX poly-
peptide per se is still not clear. Indeed, initial works havetype and mutants in COS cells. Two mutants (ATX T210A and ATX
nd the conditioned media of these cells were checked for the production
phosphodiesterase. (A) Western blot analysis of the conditioned media
eft panel: phosphodiesterase activities using the same preparations as
ls: ATX wild-type -transfected cell-derived conditioned media; shaded
symbols: ATX D202–363-transfected cell-derived conditioned media).
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factor before the lysoPLD catalytic activity was discovered
(i.e. before 2002 [2,3]). This fact was at least in part because
ATX, a.k.a. NPP2, a nucleotide pyrophosphatase at that time,
catalyzed poorly such enzymatic activity and also be cause it
bears a RGD sequence, a well-describe motif of association
with integrin, although indirect evidence was also brought by
the fact that T306A ATX, an catalytic inactive enzyme
[15,16], was not able to show any motility capacity.
ATX KO strategy was therefore clearly important in demon-
strating or inﬁrming this observation (i.e. if ATX polypeptide
was a motility factor by its structure or by its lysoPLD cata-
lytic activity). Tanaka et al. [30] showed that the ablation of
the ATX polypeptide was lethal to the embryo. The initiation
codon and ﬁrst 45 amino acids, in their strategy, was replaced
by a lacZ sequence, impairing the expression of the whole
ATX polypeptide. van Meeteren et al. [29], chose to be more
restrictive in their construct, they took oﬀ the region of the
ATX comprised between exons 5 and 8, a region which encom-
pass the catalytic site of the enzyme. In the present approach,
to the contrary of the other reported KO strategies, we decided
to maintain the expression of the whole polypeptide, albeit in a
catalytic inactive form (the T209A mutant [15,16]).
Despite the fact that the introduction of the mutation in ES
cells led to lethality, strongly suggesting that this mutated
ATX was indeed the reason for this lethality, the formal proof
that the mutated ATX was expressed at early stages of the em-
bryo development was not shown here, while it was reported in
the literature that ATX protein is detectable only after 9.5 days
in mouse embryos [32]. Indeed, the ES1 cells were screened in
RT-PCR for the detection of ATX mRNA. It was still not
detectable after 40 cycles, strongly suggesting that ATX
mRNA were not present in these cells. Only an indirect dem-
onstration that the ATX mutant was indeed expressed in cells
could be done. As reported in Fig. 5, COS cells transfected
with either the wild-type or two mutated ATX (T210A and
D202–363) were shown to be able to express the proteins as de-
tected by our anti-ATX antibody. Nevertheless, no catalytic
activity was detectable in the conditioned media of these cells,
controlled by identical experiments with the wild-type enzyme,
as already reported in the literature [15,16]. These results dem-
onstrate one more time the lethality of the ATX/ embryos.
This demonstrates for the ﬁrst time that ATX-dependent LPA
production is due to the catalytic activity of the enzyme. This
is, to our knowledge, the ﬁrst knockout mice model bearing a
single aminoacid mutation that is lethal. It is a wonderful dem-
onstration that the catalytic activity of ATX is key to the nor-
mal mouse foetal development. It also strongly suggests that
ATX is the major, if not the only – source of lysophosphatidyl
acid. Alternative technology will have to be assessed, as condi-
tional knockout after, e.g. tetracycline treatments, or targeted
KO in organs (e.g. adipose tissues) after breeding of speciﬁc
Cre-bearing animals with our strain expression the ﬂoxed
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